[{"from": "human", "value": "Provide a description of this molecule. [C][C][=Branch1][C][=O][O][C@@H1][C][C@][Branch2][Branch1][Branch2][C@@H1][Branch1][#Branch1][C][C][C][Ring1][Branch1][=O][C][=C][Ring1][#Branch2][C@][Branch2][Ring2][=Branch1][C@H1][Branch2][Ring1][#C][O][C][=Branch1][C][=O][/C][=Branch1][O][=C][/N][Branch1][Ring2][C][C][=C][C][C][=C][/C][Ring1][#C][=C][Branch1][=Branch1][C][Ring2][Ring1][Ring1][=O][O][C][O][C][C][C]"}, {"from": "gpt", "value": "The molecule is a small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents."}]